Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-11-30 5:08 pm Sale | 13D | LianBio LIAN | TANG CAPITAL PARTNERS LP | 9,320,746 8.6% | -328,273 (-3.40%) | View |
| 2023-11-28 06:00 am Purchase | 13D | Atea Pharmaceuticals, Inc. AVIR | TANG CAPITAL PARTNERS LP | 4,033,463 4.8% | 1,007,008 (+33.27%) | View |
| 2023-11-27 4:47 pm Purchase | 13G | Kinnate Biopharma Inc. KNTE | TANG CAPITAL PARTNERS LP | 2,965,715 6.3% | 2,965,715 (New Position) | View |
| 2023-11-24 1:49 pm Purchase | 13G | Aclaris Therapeutics, Inc. ACRS | TANG CAPITAL PARTNERS LP | 4,338,155 6.1% | 4,338,155 (New Position) | View |
| 2023-11-24 1:49 pm Purchase | 13D | Theseus Pharmaceuticals, Inc. THRX | TANG CAPITAL PARTNERS LP | 3,101,606 7% | 3,101,606 (New Position) | View |
| 2023-11-01 4:00 pm Purchase | 13G | LianBio LIAN | TANG CAPITAL PARTNERS LP | 9,649,019 9% | 9,649,019 (New Position) | View |
| 2023-10-13 4:53 pm Purchase | 13D | Rain Therapeutics Inc. RAIN | TANG CAPITAL PARTNERS LP | 4,024,486 14.6% | 284,145 (+7.60%) | View |
| 2023-10-10 4:00 pm Purchase | 13G | Bionomics Limited BNOX | TANG CAPITAL PARTNERS LP | 126,000,000 8.6% | 126,000,000 (New Position) | View |
| 2023-09-26 11:06 am Purchase | 13G | TransCode Therapeutics, Inc. RNAZ | TANG CAPITAL PARTNERS LP | 354,700 9.99% | 354,700 (New Position) | View |
| 2023-07-13 4:57 pm Purchase | 13G | ASLAN Pharmaceuticals Limited ASLN | TANG CAPITAL PARTNERS LP | 45,155,180 11% | 18,330,555 (+68.33%) | View |
| 2023-06-06 4:00 pm Purchase | 13G | AVROBIO, Inc. AVRO | TANG CAPITAL PARTNERS LP | 2,705,000 6.1% | 2,705,000 (New Position) | View |
| 2023-06-01 4:50 pm Purchase | 13D | Rain Therapeutics Inc. RAIN | TANG CAPITAL PARTNERS LP | 3,740,341 14.1% | 3,740,341 (New Position) | View |
| 2023-05-22 09:00 am Purchase | 13D | Atea Pharmaceuticals, Inc. AVIR | TANG CAPITAL PARTNERS LP | 3,026,455 3.6% | 3,026,455 (New Position) | View |
| 2023-05-05 4:37 pm Purchase | 13G | TCR2 Therapeutics Inc. TCRR | TANG CAPITAL PARTNERS LP | 4,215,864 10.7% | 1,476,917 (+53.92%) | View |
| 2023-05-05 4:34 pm Sale | 13D | Jounce Therapeutics, Inc. JNCE | TANG CAPITAL PARTNERS LP | 10,000 100% | -5,290,087 (-99.81%) | View |
| 2023-05-01 4:00 pm Purchase | 13G | MEI Pharma, Inc. MEIP | TANG CAPITAL PARTNERS LP | 361,084 5.4% | 361,084 (New Position) | View |
| 2023-05-01 4:00 pm Purchase | 13G | Genfit S.A. GNFT | TANG CAPITAL PARTNERS LP | 2,643,147 5.3% | 2,643,147 (New Position) | View |
| 2023-04-20 4:13 pm Purchase | 13G | Bolt Biotherapeutics, Inc. BOLT | TANG CAPITAL PARTNERS LP | 2,732,250 7.2% | 2,732,250 (New Position) | View |
| 2023-04-17 4:00 pm Purchase | 13G | InflaRx N.V. IFRX | TANG CAPITAL PARTNERS LP | 3,000,000 5.5% | 3,000,000 (New Position) | View |
| 2023-04-07 4:00 pm Unchanged | 13D | Jounce Therapeutics, Inc. JNCE | TANG CAPITAL PARTNERS LP | 5,300,087 10.2% | 0 (Unchanged) | View |